Risk assessment and aspirin use in Asian and western populations

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 943-956

  Gao, Runlin ^a   Li, Xiaoying ^b  

^a FUWAI HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Asia; Aspirin; Cardiovascular risk estimation; Western

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; WARFARIN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ATHEROSCLEROSIS; BLEEDING; BLOOD ANALYSIS; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DIABETES MELLITUS; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG UTILIZATION; ETHNIC DIFFERENCE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HEART PROTECTION; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PREVALENCE; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SEX RATIO; SMOKING HABIT; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS; VALIDATION PROCESS; ASIA; CORONARY ARTERY DISEASE; DRUG COMBINATION; EUROPE; FEMALE; MALE; UNITED STATES;

ASIA; ASPIRIN; CORONARY DISEASE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79952044712     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S9400     Document Type: Review

References (94)

1. Gaziano JM. Global burden of cardiovascular disease. In: Libby P, Bonow RO, Mann DL, et al. editors. Libby: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders; 2007:1-21.
2. American Heart Association 2004. International Cardiovascular Disease Statistics. Available from: http://www.americanheart.org/presenter.jhtml?identifier=3001008. Accessed September 14, 2009.
3. World Health Organization 2004. Atlas of Heart Disease and Stroke. Available from: http://www.who.int/cardiovascular_diseases/resources/atlas/en/index.html . Accessed September 14, 2009.
4. The George Institute. China program fact sheet. Available from www. thegeorgeinstitute.org/library/b30064_3.pdf. Accessed September 14, 2009.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
6. Leeder S, Raymond S, Greenberg M, et al. A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies. New York, NY: Columbia University, 2004.
7. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929-1938.
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
9. Mancia G, De BG, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
10. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-1660.
11. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157.
12. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481-1501.
13. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172.
14. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88-136.
15. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(6):1583-1633.
16. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2(12):e353.
17. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: Results of a national survey. Am J Prev Med. 2007;32(5):403-407.
18. Khalil MZ, Abba AA. Management of acute myocardial infarction Do we follow guidelines applied in practice? Saudi Med J. 2003;24:1234-1237.
19. Bi Y, Gao R, Patel A, et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hoapitalization: Results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J. 2009;157:509-516.
20. Zaninelli A, Kaufholz C, Schwappach D. Physicians' attitudes toward post-MI aspirin prophylaxis: Findings from an online questionnaire in Europe and Latin-America. Postgrad Med. 2009;121:44-53.
21. Zaninelli A, Hu DY, Kaufholz C, Schwappach D. Physicians' attitudes toward post-MI aspirin prophylaxis: Findings from an online questionnairein Asia-Pacific. Postgrad Med. 2010;122(1):108-117.
22. Song XT, Chen YD, Pan WQ, Lü SZ. CRACE investigators. Gender based differences in patients with acute coronary syndrome: Findings from Chinese Registry of Acute Coronary Events (CRACE). Chin Med J (Engl). 2007;120(12):1063-1067.
23. Yamazaki T, Goto S, Shigematsu H, et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007;71(7):995-1003.
24. Gaziano JM, Manson JE, Ridker PM. Primary and secondary prevention of coronary heart disease. In: Libby P, Bonow RO, Mann DL, et al. editors. Libby: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders; 2007; 1119-48.
25. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: The NHANES I follow-up study cohort. Lancet. 2008;371(9616):923-31.
26. World Health Organization. Prevention of Cardiovascular Disease. Guidelines for assessment and management of cardiovascular risk. 2007. Available from: www.who.int>...>Cardiovascular disease Guidelines. Accessed on March 17, 2010.
27. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
28. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987-1003.
29. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-315.
30. New Zealand Guidelines Group guidelines. Available at: http://www.nzgg.org.nz. Accessed January 15, 2010.
31. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men. Circulation. 2008;118:2243-2251.
32. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
33. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: Prospective open cohort study. BMJ. 2007;335:136.
34. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
35. Framingham model. Available at: http://cvrisk.mvm.ed.ac.uk/calculator/calc.asp?framingham. Accessed January 15, 2010.
36. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA.2004;291(21):2591-2599.
37. Wu YF, Liu XQ, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114(21):2217-2225.
38. Gu D, Gupta A, Muntner P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: Results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation. 2005;112(5):658-665.
39. Morimoto T, Fukui T, Lee TH, Matsui K. Application of US guidelines in other countries: Aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004;117(7):459-468.
40. Joshi P, Islam S, Reddy S, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007;297:286-294.
41. Karthikeyan G, Teo KK, Islam S, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: An analysis from the INTERHEART Study. J Am Coll Cardiol. 2009;53:244-253.
42. Enas EA, Yusuf S, Mehta J. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol. 1992;70:945-949.
43. McKeigue PM, Marmot MG. Mortality from coronary heart disease in Asian communities in London. BMJ. 1988;297(6653):903.
44. Balarajan R. Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ. 1991;302:560-564.
45. Kuller LH. Ethnic differences in atherosclerosis, cardiovascular disease and lipid metabolism. Curr Opin Lipidol. 2004;15:109-113.
46. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;150(6):396-404.
47. Chinese Society of Cardiology Chinese Medical Association. Editorial Board of Chinese Journal of Cardiology. The clinical use of aspirin in patients with atherosclerotic cardiovascular disease: 2005 Chinese Expert Consensus Document. Chin J Cardiol. 2006;34:281-284.
48. Yoon YE, Rivera JJ, Kwon DA, et al. National Cholesterol Education Panel III guidelines performance role in preventing myocardial infarction in a large cohort without a history of coronary artery disease: Korea Acute Myocardial Infarction Registry study. Prev Cardiol. 2009;12(2):109-113.
49. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation- a nationwide descriptive study in Taiwan. Clin Ther. 2008;30(9):1726-1736.
50. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-135.
51. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296(6618):313-316.
52. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT)randomized trial. Lancet. 1998;351(9118):1755-1762.
53. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.
54. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP)trial. Diabetes Care. 2003;26(12):3264-3272.
55. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351(9098):233-241.
56. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2008;300(18):2134-2141.
57. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163(17):2006-2010.
58. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98(6):746-750.
59. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomized trials. Lancet. 2009;373(9678):1849-1860.
60. Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes: Still an open question. JAMA. 2008;300(18):2180-2181.
61. Chen Z, Xu Y, Yu Q, et al. Secondary prevention of myocardial reinfarction with low dose aspirin. Chin Med Sci J. 1991;6(3): 141-144.
62. Yasue H, Ogawa H, Tanaka H, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol. 1999;83(9):1308-1313.
63. CAST Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641-1649.
64. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
65. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial. Lancet. 2004;364(9431): 331-337.
66. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomized placebo-controlled trial. Lancet. 2005;366(9497):1607-1621.
67. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluatedusing Doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111(17):2233-2240.
68. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
69. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288(19):2411-2420.
70. Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended- release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebocontrolled study. Lancet Neurol. 2008;7(10):875-884.
71. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13.
72. Hennekens CH, Sacks FM, Tonkin A, et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease. Randomized and observational comparisons of secondary prevention trials and theirmeta-analyses. Arch Intern Med. 2004;164(1):40-44.
73. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of lowdoseaspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.
74. A Study of Cardiovascular Events iN Diabetes: Available from: http://www.clinicaltrials.gov/ct2/show/NCT00135226?term=ASCEND=aspirin &rank=1. Accessed September 14, 2009.
75. Heer T, Juenger C, Gitt AK, et al. Efficacy and safety of optimizedantithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice. J Thromb Thrombolysis. 2008;28(3):325-332.
76. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: Health effects and costs. Lancet. 2007;370(9604):2054-2062.
77. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest. 2001;119 (1 Suppl):S39-S63.
78. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ. 2000;321(7270):1183-1187.
79. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA. 1998;280(22):1930-1935.
80. McQuaid K, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119(8):624-638.
81. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(S Suppl):S234-S264.
82. Leong RW. Differences in peptic ulcer between the East and the West. Gastroenterol Clin N Am. 2009;38:363-379.
83. Lee I, Lee H, Kim M, et al. Ethnic difference of Helicobacter pylori gastritis: Korean and Japanese gastritis is characterized by male- andantrum-predominant acute foveolitis in comparison with American gastritis. World J Gastroenterol. 2005;11:94-98.
84. Cole AT, Hudson N, Liew LC, Murray FE, Hawkey CJ, Heptinstall S. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment Pharmacol Ther. 1999;13(2):187-193.
85. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA. 2007;297(18):2018-2024.
86. Papathanasiou A, Goudevenos J, Tselepis AD. Aspirin resistance in cardiovascular disease: Pathogenesis, diagnosis and clinical impact. Curr Pharm Des. 2009;15:1085-1094.
87. Wang CB, Hu DY, Shi XB, Zhu ZY, Zhu JY, Yang JG. Aspirin resistance n patients taking small dose of aspirin. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006;18(4):219-223. Chinese.
88. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007;120(7):631-635.
89. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118(7):723-727.
90. Lordkipanidze M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: Truth or dare. Pharmacol Ther. 2006;112(3):733-743.
91. Patrono C, Rocca B. Drug insight: Aspirin resistance- fact or fashion? Nat Clin Pract Cardiovasc Med. 2007;4(1):42-50.
92. Japanese Primary Prevention Project with aspirin: Available from: http://www.clinicaltrials.gov/ct2/show/NCT00225849?term=JPPP&rank=1. Accessed September 14, 2009.
93. Yamasaki Y, Kim YS, Kawamori R. Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: Study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). Cardiovasc Diabetol. 2006;5:16.
94. Chang LC, Huang N, Chou YJ, Kao FY, Hsieh PC, Huang YT. Patterns of combined prescriptions of aspirin-Ginkgo biloba in Taiwan: A population-based study. J Clin Pharm Ther. 2008;33(3):243-249.